Genomic and metabolomic advances in the identification of disease and adverse event biomarkers.
Incomplete knowledge of tissue pathogenesis is hampering the identification of biomarkers for the appropriate therapeutic targets to prevent or inhibit disease processes, and the prediction and diagnosis of injury due to disease and adverse events of drug therapy. The revolution in genomics and metabolomics, combined with advanced bioinformatics and computational methods for mining such large, complex data sets, are beginning to provide critical insights into tissue injury. Such results will move us closer to the promise of personalized medicine.
Mendrick
Donna L
DL
Division of Systems Toxicology, HFT-230, National Center for Toxicological Research, US FDA, 3900 NCTR Road, Jefferson, AR 72079-4502, USA. donna.mendrick@fda.hhs.gov
Schnackenberg
Laura
L